Ephraim Resources Limited

EPA

AU000000EPA3

Biotechnology & Medical Research

End-of-day quote Australian S.E. Other stock markets 11:47:55 2017-02-27 pm EST			5-day change	1st Jan Change
0.002 ^AUD	+100.00%		+100.00%	-.--%

2020	Ephraim Resources Limited Announces Company Secretary Changes	CI
2020	Ephraim Resources Limited Announces Change of Registered Office and Principal Place of Business	CI

Ephraim Resources Limited Appoints Steven Nicols as Director

January 20, 2020 at 01:20 am EST

Ephraim Resources Limited announced the appointment of Steven Nicols as Director on 17 January 2020.

Latest news about Ephraim Resources Limited

Ephraim Resources Limited Announces Company Secretary Changes	20-01-28	CI
Ephraim Resources Limited Announces Change of Registered Office and Principal Place of Business	20-01-28	CI
Ephraim Resources Limited Appoints Peter Sing Yin Chai as Director	20-01-20	CI
Ephraim Resources Limited Appoints Steven Nicols as Director	20-01-20	CI
Ephraim Resources Limited Appoints Gregory Barry Starr as Director	20-01-20	CI
Ephraim Resources Announces Board Appointments	20-01-20	CI
Ephraim Resources Limited announced that it expects to receive AUD 0.5 million in funding	20-01-16	CI
Ephraim Resources Ltd (ASX: EPA) cancelled the acquisition of Bio-Nexus Ltd.	19-08-25	CI
Ephraim Resources Limited Announces Resignation of Timothy Laforest as Non-Executive Director	19-02-19	CI
Ephraim Resources Limited announced that it has received AUD 0.05 million in funding	18-10-30	CI
Ephraim Resources Limited Reports Audited Consolidated Earnings Result for the Year Ended June 30, 2018	18-08-31	CI
Ephraim Resources Limited Auditor Raises 'Going Concern' Doubt	18-08-30	CI
Ephraim Resources Limited Announces Cessation of Jwee Phuan Frederick Eric Ng as Director	18-07-30	CI
Ephraim Resources Limited announced that it has received AUD 0.25 million in funding	18-07-22	CI
Ephraim Resources Ltd (ASX: EPA) has signed a non-binding memorandum of understanding to acquire Bio-Nexus Ltd.	18-07-09	CI
Ephraim Resources Limited announced that it expects to receive AUD 0.25 million in funding	18-07-09	CI
Ephraim Resources Limited Announces Board Changes	18-06-17	CI
Ephraim Resources Limited Announces Consolidated Earnings Results for the Half Year Ended December 31, 2017	18-03-02	CI
Andrew Chan Resigns as Non-Executive Director of Ephraim Resources Limited	17-11-29	CI
Ephraim Resources Limited Reports Audited Consolidated Earnings Result for the Year Ended June 30, 2017	17-08-31	CI
Ephraim Resources Limited Auditor Raises 'Going Concern' Doubt	17-08-30	CI
Alumi Envirotech Pte Ltd cancelled acquisition of Ephraim Resources Limited in a reverse merger transaction .	17-07-11	CI
Ephraim Resources Limited Appoints Andrew Chan as Non-Executive Director	17-06-22	CI
Ephraim Resources Limited Announces Consolidated Earnings Results for the Half Year Ended December 31, 2016	17-02-28	CI
Ephraim Resources Limited Announces Board Changes	17-01-30	CI

Chart Ephraim Resources Limited

Duration

Period

More charts

Ephraim Resources Limited is engaged in the business of agricultural biogenetics research and experimentation, licensing and consultancy. The Company focuses on nipah palm breeding, tissue culture, cultivation and plantation, and the conversion of sap from the nipah palm to sugar and ethanol. The Company operates through two segments: Australia and Indonesia. It has developed a methodology to develop nipah palm fit for cropping on an industrial scale and optimize the use of degraded land for nipah palm plantations in Indonesia, and to produce sugar. The Company, through its subsidiary, PT First Flower (PTFF), has completed plantation trials and has rights over 11,800 hectares of land for nipah palm cultivation. PTFF has land use rights in the Meranti District, Riau province for over 8,000 hectares for non-wood products; in the Tanah Laut District, South Kalimantan province for over 1,200 hectares, and in the Kota Baru District, South Kalimantan province for over 2,600 hectares.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EPHRAIM RESOURCES LIMITED	-.--%	2.09M
IQVIA HOLDINGS INC.	+2.14%	42.11B
LONZA GROUP AG	+49.28%	40.08B
MODERNA, INC.	+7.79%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+6.71%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-21.88%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.68%	11.94B
MEDPACE HOLDINGS, INC.	+27.59%	11.66B
UNITED THERAPEUTICS CORPORATION	+8.15%	11.01B

Other Biotechnology & Medical Research